Bristol Myers Squibb has made significant cuts to its workforce since last year as part of a strategic reorganization aimed ...

On the FDA’s docket this month are two expansion bids, one for GSK’s asthma drug Nucala into COPD and another for Merck’s ...

BNT327, a PD-L1/VEGF therapy, is still currently being manufactured in China, but BioNTech is working to establish a ...

The FDA accepted Novo Nordisk's NDA for an oral formulation of Wegovy. The agency is expected to release its verdict on the ...

The cell and gene therapy space in recent months has hit several speedbumps, including layoffs, dropped drugs and ...

The FDA’s user free programs account for just under half of the agency’s budget—money that could be imperiled by the recent ...

Beam Therapeutics and Verve Therapeutics have each built their lead candidates on a technique billed as a safer alternative ...

The new policy, revealed by the Department of Health and Human Services on Wednesday, would make vaccines “less available and ...

No Patient Left Behind says that drug value assessments used in countries like Canada and Germany undervalue innovative ...

Jefferies analysts said Moderna’s first quarter was “in line,” with a miss on revenue offset by a beat on earnings per share.

Following the recent discontinuations of assets in Alzheimer’s and migraine, AstraZeneca is stepping away from neuro ...

Like fellow Big Pharmas Eli Lilly and Johnson & Johnson, Amgen is urging the Trump administration to consider tax policy ...